Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessio Cortellini

Showing results (1-10 of 255) with videos related to

Pageof 26
Sort By:
JTO Clinical and Research Reports|September 30, 2021
The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLCAlessio Cortellini
European Journal of Cancer (Oxford, England : 1990)|September 22, 2020
Letter to the Editor: considerations about recent findings on long-term adverse events of PD-1/PD-L1 checkpoint inhibitorsOlga Nigro, Alessio Cortellini
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2023
Antibiotic Therapy: The Cornerstone of Iatrogenic Resistance to Immune Checkpoint InhibitorsDavid J Pinato, Alessio Cortellini
Annals of Translational Medicine|October 29, 2019
The way towards tailored treatment for metastatic renal cancer patients in the <i>omics</i> era: are we getting a "transcriptomic compass"?Melissa Bersanelli, Alessio Cortellini, Sebastiano Buti
The New England Journal of Medicine|June 1, 2022
Reassessing Human Adipose TissueSebastiano Buti, Alessio Cortellini, Melissa Bersanelli
Human Vaccines & Immunotherapeutics|January 11, 2021
The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the "inflamed tumor" to the "inflamed patient"Melissa Bersanelli, Alessio Cortellini, Sebastiano Buti
The Lancet. Oncology|December 25, 2019
Unlocking the secret of the obesity paradox in renal tumoursMatteo Santoni, Alessio Cortellini, Sebastiano Buti
Translational Lung Cancer Research|March 14, 2022
One more piece to SOLIDify our knowledge on the impact of SARS-CoV-2 in patients with cancerAlfredo Addeo, Alessio Cortellini, Giuseppe Luigi Banna
JAMA Dermatology|January 24, 2024
Association of Survival With Immune-Related Adverse Events-Time to Consider the Duration of TreatmentYu Fujiwara, Alessio Cortellini, Abdul Rafeh Naqash
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2023
Diabetes and Immune Checkpoint Inhibitors-ResponseAlessio Cortellini, Antonio D'Alessio, David J Pinato
Pageof 26

Showing results (1-10 of 255) with videos related to

Sort By:
Pageof 26
JTO Clinical and Research Reports|September 30, 2021
The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLCAlessio Cortellini
European Journal of Cancer (Oxford, England : 1990)|September 22, 2020
Letter to the Editor: considerations about recent findings on long-term adverse events of PD-1/PD-L1 checkpoint inhibitorsOlga Nigro, Alessio Cortellini
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2023
Antibiotic Therapy: The Cornerstone of Iatrogenic Resistance to Immune Checkpoint InhibitorsDavid J Pinato, Alessio Cortellini
Annals of Translational Medicine|October 29, 2019
The way towards tailored treatment for metastatic renal cancer patients in the <i>omics</i> era: are we getting a "transcriptomic compass"?Melissa Bersanelli, Alessio Cortellini, Sebastiano Buti
The New England Journal of Medicine|June 1, 2022
Reassessing Human Adipose TissueSebastiano Buti, Alessio Cortellini, Melissa Bersanelli
Human Vaccines & Immunotherapeutics|January 11, 2021
The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the "inflamed tumor" to the "inflamed patient"Melissa Bersanelli, Alessio Cortellini, Sebastiano Buti
The Lancet. Oncology|December 25, 2019
Unlocking the secret of the obesity paradox in renal tumoursMatteo Santoni, Alessio Cortellini, Sebastiano Buti
Translational Lung Cancer Research|March 14, 2022
One more piece to SOLIDify our knowledge on the impact of SARS-CoV-2 in patients with cancerAlfredo Addeo, Alessio Cortellini, Giuseppe Luigi Banna
JAMA Dermatology|January 24, 2024
Association of Survival With Immune-Related Adverse Events-Time to Consider the Duration of TreatmentYu Fujiwara, Alessio Cortellini, Abdul Rafeh Naqash
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2023
Diabetes and Immune Checkpoint Inhibitors-ResponseAlessio Cortellini, Antonio D'Alessio, David J Pinato
Pageof 26